Literature DB >> 18160543

Mini-Suffering State Examination: suffering and survival of end-of-life cancer patients in a hospice setting.

Abraham Adunsky1, Bechor Zvi Aminoff, Marina Arad, Michaela Bercovitch.   

Abstract

The objective of this study was to evaluate suffering of end-of-life cancer patients during their final hospice stay and the possible interrelations with survival. A cohort of consecutive patients hospitalized in an inpatient cancer hospice of a tertiary hospital was used for this study. Patients were evaluated upon admission and once weekly by the Mini-Suffering State Examination (MSSE). The distribution of patients for each MSSE score group, changes in MSSE scores (total and for each item of scale), and MSSE interrelation with clinical parameters associated with patients' condition during hospitalization were studied. In addition, the interrelation of MSSE score and survival was examined. Documentation of a high suffering level by the MSSE scale helps in identifying end-of-life cancer patients expected to benefit from enrollment in a hospice setting, provides quantitative information about various symptom dimensions, and may improve medical management and facilitate communication between these patients and caregivers.

Entities:  

Mesh:

Year:  2007        PMID: 18160543     DOI: 10.1177/1049909107307374

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  2 in total

1.  Evaluation of the palliative symptom burden score (PSBS) in a specialised palliative care unit of a university medical centre - a longitudinal study.

Authors:  Katharina Fetz; Hendrik Vogt; Thomas Ostermann; Andrea Schmitz; Christian Schulz-Quach
Journal:  BMC Palliat Care       Date:  2018-07-07       Impact factor: 3.234

2.  Suffering measurement instruments in palliative care: protocol for a systematic psychometric review.

Authors:  Daniel Gutiérrez Sánchez; Rafael Gómez García; Isabel María López-Medina; Antonio I Cuesta-Vargas
Journal:  BMJ Open       Date:  2019-04-03       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.